Petros Grivas: Ipilimumab/nivolumab vs standard care in non-clear cell renal cell cancer by Andrea Apolo

Petros Grivas shared a post by Andrea Apolo on X:

“Agree with Andrea Apolo excellent presentation on this trial & great discussion by Manuela Schmidinger, The European Society for Medical Oncology, Toni Choueiri, Brian Rini and Uromigos.”

Quoting Andrea Apolo’s post:

“SUNNIFORECAST phase 2 randomised trial of ipilimumab/nivolumab vs standard of care in non-clear cell renal cell cancer show a 12-month OS p=0.014 with no PFS benefit.

This was also seen in papillary and chromophobe subgroup analysis.”

Source: Petros Grivas/X and Andrea Apolo/X

Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.

Andrea Apolo is the Chief of the Bladder Cancer Section of the Genitourinary Malignancies Branch and Director of the Bladder Cancer and Genitourinary Tumors Multidisciplinary Clinic at the National Cancer Institute (USA). Apolo received a 2011 National Institutes of Health Award of Merit, the 2014 Lasker Clinical Research Scholars Program Award, the 2018 National Cancer Institute’s Director’s Award for Clinical Science, the 2018 Advancing Cancer Treatment Award for leadership in genitourinary clinical trial patient access, and the 2020 Arthur S. Flemming Award for leaders who make an impact in public service.